Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02330965 · ClinicalTrials.gov registry record
Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis
A clinical trial of Secondary Progressive Multiple Sclerosis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 36
- Enrollment target
- 13
- Study locations
NCT02330965: Completed study of Secondary Progressive Multiple Sclerosis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT02330965 is a study of Secondary Progressive Multiple Sclerosis that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 36 participants, below the 493-participant average among 8 other Secondary Progressive Multiple Sclerosis trials with a reported enrollment target (93% lower). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02330965, a study of Secondary Progressive Multiple Sclerosis, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 36 participants
- Enrollment target
- 13
- Study locations
Study Summary
The primary goal of this study is to evaluate the effects of BAF312 (siponimod) on select immune and neuronal (nerve) cells by examining laboratory specimens (blood and/or spinal fluid) at multiple time points, prior to, and following the initiation of BAF312 or placebo treatment, in patients with Secondary Progressive Multiple Sclerosis (SPMS) who are enrolled in a clinical trial (NCT01665144) to evaluate the effectiveness and safety of BAF312.
Primary Outcome
Evaluation (BAF312 versus placebo) of dominant cytokines produced by myelin basic protein (MBP)-stimulated peripheral blood mononuclear cells (PBMCs), measured by ELISpot.
Conditions Studied
Interventions
- PROCEDURE Blood Draw
- PROCEDURE CSF collection by lumbar puncture (Optional)
Study Locations (13)
California
- Jordan Research & Education Institute: Sutter Alta Bates Summit - Berkeley
- University of Southern California - Los Angeles
- University of California, Davis - Sacramento
Michigan
- University of Michigan Health System -Multiple Sclerosis Center - Ann Arbor
- Henry Ford Health System - Detroit
Colorado
- University of Colorado - Aurora
Minnesota
- Minneapolis Clinic of Neurology - Golden Valley
New Mexico
- University of New Mexico: Health Sciences Center - Albuquerque
New York
- South Shore Neurologic Associates - Multiple Sclerosis Care Center - Patchogue
North Carolina
- Carolinas Medical Center (CMC) - Charlotte
Ohio
- Cleveland Clinic: Mellen Center for Multiple Sclerosis - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-07-12 |
What the finished NCT02330965 record still lists
NCT02330965 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 493-participant average among 8 other Secondary Progressive Multiple Sclerosis trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Secondary Progressive Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Blood Draw is the first listed.
NCT02330965 lists 13 locations in 10 states (California, Michigan, Colorado).
Frequently Asked Questions
What is clinical trial NCT02330965 about?
NCT02330965 is a clinical study titled "Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis". The primary goal of this study is to evaluate the effects of BAF312 (siponimod) on select immune and neuronal (nerve) cells by examining laboratory specimens (blood and/or spinal fluid) at multiple time points, prior to, and following the initiation of BAF312 or placebo treatment, in patients with S...
What is the current status of trial NCT02330965?
This trial is currently completed. The enrollment target is 36 participants. The study started on 2014-12. Estimated completion is 2017-07-12.
What conditions does trial NCT02330965 study?
This clinical trial studies the following conditions: Secondary Progressive Multiple Sclerosis.
What interventions are being tested in trial NCT02330965?
The interventions under investigation include: Blood Draw (PROCEDURE), CSF collection by lumbar puncture (Optional) (PROCEDURE).
Who is sponsoring clinical trial NCT02330965?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02330965 being conducted?
This trial has 13 study locations across California, Colorado, Michigan, Minnesota, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Secondary Progressive Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02330965's enrollment target sits among peer trials
36 7th of 8 higher than 2 of 8 other Secondary Progressive Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Secondary Progressive Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
RECRUITING · Phase 2
-
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
RECRUITING · Phase 3
-
Functional Outcomes From Diets in Multiple Sclerosis
RECRUITING · NA
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
RECRUITING · Phase 3
-
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia